QuidelOrtho Corporation (QDEL) Stock Price & Analysis
QuidelOrtho Corporation (QDEL) closed at USD 14.01 on Wednesday, October 28, 2026, up 3.09% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 13.59; the Oct 28, 2026 session ranged USD 13.45–14.56 on volume of 1,621,186 shares. Market capitalization is $960.74M, with a 52-week range of USD 9.92–35.58 (NMS). Source: Nexqual, retrieved October 29, 2026 at 07:03 UTC.
Also available as compact Markdown for AI agents: nexqual.com/QDEL.md
Key facts (QDEL)
- Last four reported quarters (through Jun 28, 2026): revenue $2.67B, net income -$1.05B (-39.2% margin), free cash flow -$211M (SEC filings).
- Analysts: Hold (mean 3.33 on a 1–5 scale) (3 analysts), mean target USD 14.67 (range 12–20).
- Total return with dividends: 1Y -49.9% vs S&P 500 +13.6%; 5Y -89.5% vs S&P 500 +79.8%.
- Next earnings: 2026-11-03, EPS estimate USD 0.18, revenue estimate $628M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (QDEL)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.70B | $3.27B | $3.00B | $2.78B | $2.73B | $2.67B |
| Operating income | $906M | $844M | $139M | -$1.96B | -$919M | -$825M |
| Net income | $704M | $549M | -$10.1M | -$2.05B | -$1.13B | -$1.05B |
| EPS (diluted) | $16.43 | $9.56 | -$0.15 | -$30.54 | -$16.69 | — |
| Free cash flow | $513M | $744M | $70.9M | -$112M | -$83.0M | -$211M |
| Operating margin | 53.3% | 25.8% | 4.6% | -70.5% | -33.7% | -30.8% |
| Net margin | 41.5% | 16.8% | -0.3% | -73.7% | -41.5% | -39.2% |
| Revenue growth | +2.2% | +92.3% | -8.2% | -7.2% | -1.9% | — |
| Cash + short-term investments | $829M | $345M | $167M | $98.3M | — | — |
| Total debt | $1.0M | $2.86B | $2.56B | $2.83B | $2.88B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 28, 2026) (QDEL)
P/S 0.4x · P/B 0.5x · FCF yield -21.98% · Earnings yield -109.12%
Analysts (QDEL)
Consensus Hold (mean 3.33 on a 1–5 scale), 3 analysts; mean target USD 14.67 (low 12, high 20).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-08 | Citigroup | Target raised | Neutral | $13 → $18 |
| 2026-07-01 | JP Morgan | Target raised | Underweight | $11 → $12 |
Total return (dividends reinvested) (QDEL)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -49.9% | -89.5% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | -50.0% | -36.2% |
| Volatility (annualized) | 92.8% | 61.7% |
| Max drawdown | -71.8% (Jan 2026→May 2026) | -93.6% (Dec 2021→May 2026) |
QDEL earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | $0.13 | −$0.05 | Beat +$0.18 | — |
| — | Quarter ended Mar 31, 2026 | −$0.04 | $0.36 | Miss −$0.40 | — |
| — | Quarter ended Dec 31, 2025 | $0.46 | $0.42 | Beat +9.5% | — |
| — | Quarter ended Sep 30, 2025 | $0.80 | $0.47 | Beat +70.2% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
QDEL recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 7, 2026 | Schedule 13G/A | FMR LLC, Abigail P. Johnson: 5.8% of shares, passive 5%+ holder (amended) |
| Sep 23, 2026 | 8-K | Entered a material agreement “On September 23, 2026, QuidelOrtho Corporation (the "Company") entered into Amendment No. 1 (the "Amendment") to its existing credit agreement, dated as of August 21, 2025 (as amended by the Amendment, the "Credit Agreement"), by and among the Company, as borrower, Bank of America, N.A., as administrative agent and swing line lender ("Bank of America"), and the other lenders and L/C issuers party thereto (together with Bank of America, the "Lenders"). Pursuant to the Credit Agreement, the Lenders provided the…” |
| Aug 14, 2026 | Schedule 13G/A | Newtyn Management, LLC, Newtyn TE Partners, LP: 9.7% of shares, passive 5%+ holder (amended) |
| Aug 14, 2026 | Schedule 13G/A | T. Rowe Price Investment Management, Inc.: 2.6% of shares, passive 5%+ holder (amended) |
| Aug 13, 2026 | Schedule 13G | Invesco Ltd.: 5.1% of shares, passive 5%+ holder |
| Aug 7, 2026 | 10-Q | Quarterly report · period ended Jun 28, 2026 |
| Aug 6, 2026 | 8-K | Quarterly results |
| Aug 5, 2026 | Schedule 13G/A | Neuberger Berman Group LLC, Neuberger Berman Investment Advisers LLC: 4.9% of shares, passive 5%+ holder (amended) |
| Jul 8, 2026 | Schedule 13G | Neuberger Berman Group LLC, Neuberger Berman Investment Advisers LLC: 5.2% of shares, passive 5%+ holder |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
QDEL revenue by business segment (quarter ended Jun 28, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| North America | $327.4M | 51.9% | +5.4% |
| EMEA | $91.2M | 14.5% | +4.5% |
| JPAC | $74.3M | 11.8% | +2.9% |
| Latin America | $70.2M | 11.1% | +16.4% |
| China | $67.8M | 10.7% | -18.7% |
| Total revenue | $630.9M | 100% | — |
QDEL revenue by region (fiscal year ended Dec 28, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Domestic Country | $1.44B | 52.6% | -8.4% |
| Foreign Country | $1.29B | 47.4% | +6.5% |
| Total revenue | $2.73B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
QDEL suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Competitor | Siemens | “Some of our principal competitors include, among others, Abbott Laboratories, bioMérieux, Bio-Rad, Danaher, Diasorin, Hologic, Qiagen, Revvity, Roche, Siemens Healthineers, Thermo Fisher Scientific, Waters Corporation (acquired BD Diagnostics division) and Wermerson Immuncor.” |
| Competitor | Thermo Fisher (TMO) | “Some of our principal competitors include, among others, Abbott Laboratories, bioMérieux, Bio-Rad, Danaher, Diasorin, Hologic, Qiagen, Revvity, Roche, Siemens Healthineers, Thermo Fisher Scientific, Waters Corporation (acquired BD Diagnostics division) and Wermerson Immuncor.” |
Quoted from the company's 10-K filed Feb 19, 2026.
QDEL customer concentration
In the period ended Jun 28, 2026, a single direct customer accounted for 11% of revenue, per the company's 10-Q filed Aug 7, 2026. The company does not name it.
QDEL analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.18 | $0.93 | -80.9% | $627.7M | 1 |
| Next quarter (ends Dec 2026) | $0.47 | $0.97 | -51.9% | $665.3M | 1 |
| Current fiscal year (ends Dec 2026) | $0.77 | $1.85 | -58.1% | $2.54B | 2 |
| Next fiscal year (ends Dec 2027) | $1.43 | $2.46 | -41.9% | $2.59B | 2 |
Key Statistics (as of October 29, 2026 at 07:03 UTC)
| Price | USD 14.01 |
|---|---|
| Change | ▲ 3.09% (up) |
| Previous Close | USD 13.59 |
| Open | USD 13.45 |
| Day Range | USD 13.45 – 14.56 |
| 52-Week Range | USD 9.92 – 35.58 |
| Volume | 1,621,186 shares |
| Market Cap | $960.74M |
| Exchange | NMS |
Technical Analysis (QDEL)
Nexqual's technical model rates QDEL "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 29, 2026 at 07:03 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.48 (neutral) |
| vs SMA50 | Above (USD 12.79) |
| MACD | 0.42 (positive) |
Analyst Ratings (QDEL)
Wall Street analysts rate QDEL "Hold" based on 3 analysts, with a mean price target of USD 14.67 (range USD 12–20), per Nexqual as of October 29, 2026 at 07:03 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 14.67 |
| High Target | USD 20 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 1 / 1 / 1 |
Earnings (QDEL)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD 0.18 |
| Revenue Estimate | $627.73M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.13 vs est -0.05 ▲ beat |
| 2026-03-31 | USD -0.04 vs est 0.36 ▼ miss |
| 2025-12-31 | USD 0.46 vs est 0.42 ▲ beat |
| 2025-09-30 | USD 0.8 vs est 0.47 ▲ beat |
Source: Nexqual, October 29, 2026 at 07:03 UTC.
Financials & Fundamentals (QDEL)
| Total Revenue | $2.67B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +2.80% |
| Gross Margin | +44.86% |
| Operating Margin | -2.09% |
| Profit Margin | -39.20% |
| ROE | -45.91% |
| Debt / Equity | 1.73 |
| Current Ratio | 1.39 |
| Total Cash | $123.40M |
| Total Debt | $3.08B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$211.20M (-7.9% of revenue) |
Source: Nexqual, October 29, 2026 at 07:03 UTC.
Financial Health Score (QDEL)
Nexqual rates QuidelOrtho Corporation's overall financial health "Weak" across five dimensions, as of October 29, 2026 at 07:03 UTC.
| Growth | Weak — Revenue -2% YoY (annual), declining |
|---|---|
| Profitability | Mixed — Gross margin 45%, operating -31% (last 12 months) |
| Balance Sheet | Weak — $123M cash vs $3.08B debt |
| Cash Flow | Weak — FCF negative: -$211M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -59%, ROA -18.3% (last 4 quarters, SEC) |
Ownership (QDEL)
| Insider Ownership | +0.92% |
|---|---|
| Institutional Ownership | +124.09% |
| Shares Outstanding | 68.58M |
| Float | 61.15M |
| Short % of Float | +25.83% |
Source: Nexqual, October 29, 2026 at 07:03 UTC.
Leadership (QDEL)
QuidelOrtho Corporation is led by Brian J. Blaser, President, CEO & Director, per Nexqual as of October 29, 2026 at 07:03 UTC.
| President, CEO & Director | Brian J. Blaser |
|---|---|
| Executive VP of Research & Development and CTO | Jonathan P. Siegrist |
| Chief Financial Officer & Principal Financial Officer | Micah Young |
| Vice President of Investor Relations | Juliet C. Cunningham |
| Vice President of Global Marketing & Corporate Communications | Lisa S. Hayes |
Major Backers & Investors (QDEL)
Notable institutional backers of QuidelOrtho Corporation include FMR, LLC, Newtyn Management, Llc, Fidelity, according to Nexqual as of October 29, 2026 at 07:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 10.74% |
| Newtyn Management, Llc | 9.66% |
| Fidelity | 6.92% |
| Neuberger Berman Group, LLC | 5.15% |
| Invesco | 5.07% |
| American Century Companies Inc | 4.82% |
| Rubric Capital Management LP | 4.82% |
| AIM Sector Funds (Invesco Sector Funds)-Invesco Small Cap Value Fund | 4.4% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 16.34% |
| Vanguard Group | 10.51% |
Source: Nexqual, October 29, 2026 at 07:03 UTC.
From QuidelOrtho Corporation's Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Many of our proprietary processes are vertically integrated to facilitate reliability and quality advantages.
- Our global infrastructure and commercial reach support our customers across more than 140 countries and territories with quality diagnostics, a broad test portfolio and market-leading service.
- The FDA's current guidance entitled "Guidance for Industry and FDA Staff: Recommendations for Clinical Laboratory Improvement Amendments of 1988 CLIA Waiver Applications for Manufacturers of In Vitro Diagnostic Devices" sets forth requirements for obtaining a CLIA waiver, which are onerous and have increased the time and cost we are required to spend to obtain a CLIA waiver.
- For example, the California Consumer Privacy Act of 2018, as amended by the CCPA, creates individual privacy rights for California consumers and imposes privacy and data security obligations on certain entities that do business in California, including to provide specific disclosures in privacy notices, to provide rights to California residents in relation to their personal information, and to conduct audits for certain higher risk data processing.
Partnerships
- We continue to focus our R&D efforts on the following areas: •creation of new and improved products for use by our customers, including new and improved assays and software; •support of important life-cycle-management efforts to maintain our current on-market portfolio of products; and •pursuit of collaboration with other companies for new and existing products and markets.
- Under the Grifols Agreement, we share with Grifols the profits from our production and sale of Hepatitis and HIV diagnostics products, along with certain expenses related to the collaboration.
Legal & Regulatory Risks (Item 1A, quoted)
- Regulation of Our Industry and Products
- Our business is subject to substantial regulatory oversight, and our failure to comply with applicable regulations may result in significant costs or, in certain circumstances, the suspension or withdrawal of previously obtained regulatory approvals, product recalls, seizure of products or injunctions against the distribution of our products, operating restrictions and criminal prosecution.
- The FDA and corresponding foreign regulatory agencies may require post-market testing and surveillance to monitor the performance of cleared or approved products or may place conditions on any product clearances or approvals that could restrict the commercial applications of those products.
- We may encounter challenges entering into contracts with government entities due to government-sponsored tendering requirements, and any contracts that we have entered into or will enter into with government entities may involve future funding, compliance and penalties risks.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INSP | Inspire Medical Systems, Inc. | USD 70.97 | ▼ 0.46% |
| ESTA | Establishment Labs Holdings Inc | USD 68.97 | ▲ 3.02% |
| BFLY | Butterfly Network, Inc. | USD 7.81 | ▲ 5.83% |
| UFPT | UFP Technologies, Inc. | USD 286 | ▼ 3% |
| TMDX | TransMedics Group, Inc. | USD 66.9 | ▼ 4.06% |
| ALMR | Alamar Biosciences, Inc. | USD 34.3 | ▲ 7.42% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 07:03 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt